BCAX

Bicara Therapeutics Inc

17.61

Oct 22 • 3:59 PM ET -0.30 (-1.68%)

17.61

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: GMAB KURA CBIO SMMT XNCR JANX EXEL IDYA CHRS MRK

| Held by: VTI XBI IWM VXF IWO IBB DFAS VTWO SCHA FESM

Scroll to Statements

Index	RUT
Market Cap	1.17B
Enterprise Value	669.21M
Income	-185.36M
Sales	0.00M
Book/sh	7.11
Cash/sh	7.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	103
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.48
P/C	2.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.59
Current Ratio	11.59
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.09
EPS next Y	-3.62
EPS next Q	-0.82
EPS this Y	-35.78%
EPS next Y	-5.75%
EPS next 5Y	-10.68%
EPS past 3/5Y	-53.65% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-63.70%
Sales Y/Y TTM	-
EPS Q/Q	-62.50%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-0.02% -

Insider Own	33.86%
Insider Trans	-0.74%
Inst Own	77.42%
Inst Trans	-2.09%
ROA	-38.38%
ROE	-41.01%
ROIC	-39.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.45%
SMA50	-16.53%
SMA200	-17.44%
Trades

Shs Outstand	65.93M
Shs Float	43.76M
Short Float	24.44%
Short Ratio	15.80
Short Interest	10.69M
52W High	30.99 -43.18%
52W Low	13.70 28.54%
Volatility	6.11% 5.85%
ATR (14)	1.06
RSI (14)	40.06
Beta	-0.70
Rel Volume	1.21
Avg Volume	676.77K
Volume	816,949

Perf Week	-0.06%
Perf Month	-14.03%
Perf Quarter	-34.83%
Perf Half Y	-22.90%
Perf YTD	4.63%
Perf Year	7.05%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.15
Target Price	35.09
Prev Close	17.91
Price	17.61
Change %	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$35
May-11-26	Initiated	Guggenheim	Buy	$42
Mar-25-26	Initiated	BofA Securities	Buy	$35
Jan-29-26	Initiated	Citizens JMP	Mkt Perform	$31
Jan-08-26	Initiated	BTIG Research	Buy	$28
Dec-18-25	Initiated	Mizuho	Neutral	$18
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Oct-05-26 08:30AM	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-26 08:30AM	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-26 08:30AM	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-26 10:17AM	Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances (InvestorsHub) -14.32%
07:30AM	Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth (GlobeNewswire)
08:30AM	Loading…
Aug-04-26 08:30AM	Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET (GlobeNewswire)
Jul-28-26 08:30AM	Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors (GlobeNewswire)
Jul-02-26 08:30AM	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-26 05:00PM	Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC (GlobeNewswire)
May-13-26 08:30AM	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.21%
May-12-26 03:03AM	Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-11-26 07:30AM	Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-04-26 08:30AM	Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET (GlobeNewswire)
Apr-03-26 08:30AM	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-26 08:00PM	Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade (Quartz)
07:00PM	Loading…
Mar-30-26 07:00PM	Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-26 02:50PM	Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera (Proactive)
Mar-23-26 08:30AM	Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET (GlobeNewswire)
Mar-06-26 05:47AM	Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference (MarketBeat)
Mar-04-26 08:30AM	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 04:01PM	Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-24-26 11:13PM	Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.82%
04:01PM	Bicara Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-23-26 11:10AM	Bicara Therapeutics Shares New FICERA Data, Eyes Less Frequent Dosing in Head & Neck Cancer (MarketBeat) +5.94%
08:30AM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 04:30PM	Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen (GlobeNewswire) +6.42%
Feb-05-26 08:30AM	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.76%
Jan-13-26 01:08AM	Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial (MarketBeat)
Jan-12-26 08:00AM	Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook (GlobeNewswire)
08:00AM	Loading…
Dec-15-25 08:00AM	Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 (GlobeNewswire)
Dec-06-25 08:00AM	Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 (GlobeNewswire)
Dec-01-25 07:00AM	Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 (GlobeNewswire) -6.63%
Nov-10-25 07:30AM	Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
Oct-13-25 07:30AM	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC (GlobeNewswire)
Aug-27-25 04:01PM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 09:55AM	Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 07:30AM	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire) -5.56%
Jun-03-25 04:01PM	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +11.21%
Jun-01-25 01:12PM	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 (GlobeNewswire)
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena)
May-27-25 01:59PM	Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update (Insider Monkey) +7.66%
May-26-25 09:14AM	Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients (Insider Monkey)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily) -40.80%
May-22-25 05:00PM	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting (GlobeNewswire) +7.33%
May-13-25 07:30AM	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -8.10%
Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVID RABEN	Officer	Oct 21 '26	Proposed Sale	18.12	24,777	449,026		Oct 21 04:55 PM
Cohlhepp Ryan	President, COO & Interim CEO	Sep 08 '26	Option Exercise	3.79	17,500	66,322	199,141	Sep 10 04:23 PM
Cohlhepp Ryan	President, COO & Interim CEO	Sep 08 '26	Sale	22.90	17,500	400,716	181,641	Sep 10 04:23 PM
Hyep Ivan	Officer	Sep 08 '26	Proposed Sale	22.64	12,500	283,000		Sep 08 04:05 PM
Cohlhepp Ryan	Officer	Sep 08 '26	Proposed Sale	22.64	17,500	396,200		Sep 08 04:04 PM
Hyep Ivan	Chief Financial Officer	Aug 10 '26	Option Exercise	3.79	12,500	47,372	142,355	Aug 12 04:19 PM
Hyep Ivan	Chief Financial Officer	Aug 10 '26	Sale	27.97	12,500	349,591	129,855	Aug 12 04:19 PM
Mazumdar Claire	Chief Executive Officer	Aug 10 '26	Option Exercise	3.79	10,000	37,898	372,152	Aug 12 04:19 PM
Mazumdar Claire	Chief Executive Officer	Aug 10 '26	Sale	27.98	10,000	279,750	362,152	Aug 12 04:19 PM
Cohlhepp Ryan	President and COO	Aug 10 '26	Option Exercise	3.79	18,750	71,059	200,391	Aug 12 04:19 PM
Cohlhepp Ryan	President and COO	Aug 10 '26	Sale	27.98	18,750	524,533	181,641	Aug 12 04:19 PM
Hyep Ivan	Officer	Aug 10 '26	Proposed Sale	27.83	12,500	347,875		Aug 10 04:18 PM
Cohlhepp Ryan	Officer	Aug 10 '26	Proposed Sale	27.83	18,750	521,812		Aug 10 04:16 PM
Mazumdar Claire	Officer	Aug 10 '26	Proposed Sale	27.83	10,000	278,300		Aug 10 04:09 PM
Mazumdar Claire	Chief Executive Officer	Jul 10 '26	Option Exercise	3.79	10,000	37,898	372,152	Jul 14 04:22 PM
Mazumdar Claire	Chief Executive Officer	Jul 10 '26	Sale	28.42	10,000	284,198	362,152	Jul 14 04:22 PM
Cohlhepp Ryan	President and COO	Jul 08 '26	Option Exercise	3.79	18,750	71,059	210,391	Jul 10 04:10 PM
Cohlhepp Ryan	President and COO	Jul 08 '26	Sale	28.98	28,214	817,585	182,177	Jul 10 04:10 PM
Cohlhepp Ryan	President and COO	Jul 09 '26	Sale	29.00	536	15,544	181,641	Jul 10 04:10 PM
Hyep Ivan	Chief Financial Officer	Jul 08 '26	Option Exercise	3.79	12,500	47,372	157,855	Jul 10 04:10 PM
Hyep Ivan	Chief Financial Officer	Jul 08 '26	Sale	28.85	28,000	807,672	129,855	Jul 10 04:10 PM
Mazumdar Claire	Officer	Jul 10 '26	Proposed Sale	29.68	10,000	296,800		Jul 10 04:04 PM
DAVID RABEN	Officer	Jul 08 '26	Proposed Sale	28.56	50,000	1,428,080		Jul 08 04:30 PM
Cohlhepp Ryan	Officer	Jul 08 '26	Proposed Sale	30.25	28,750	869,688		Jul 08 04:11 PM
Hyep Ivan	Officer	Jul 08 '26	Proposed Sale	30.25	28,000	847,000		Jul 08 04:05 PM
Lara Meisner	Officer	Jul 07 '26	Proposed Sale	29.77	1,000	29,774		Jul 07 04:06 PM
DAVID RABEN	Officer	Jun 25 '26	Proposed Sale	26.49	50,000	1,324,650		Jun 25 04:07 PM
Meisner Lara	Former Chief Legal Officer	Jun 01 '26	Proposed Sale	20.64	71,390	1,473,716		Jun 01 04:02 PM
Hyep Ivan	Chief Financial Officer	May 21 '26	Option Exercise	3.79	9,200	34,866	154,555	May 26 05:48 PM
Hyep Ivan	Chief Financial Officer	May 21 '26	Sale	20.42	9,200	187,883	145,355	May 26 05:48 PM
Raben David	Officer	May 26 '26	Proposed Sale	21.82	5,500	120,010		May 26 04:02 PM
Hyep Ivan	Officer	May 21 '26	Proposed Sale	20.42	9,200	187,883		May 21 04:02 PM
Mazumdar Claire	Chief Executive Officer	May 18 '26	Option Exercise	3.79	15,000	56,847	377,152	May 20 04:07 PM
Mazumdar Claire	Chief Executive Officer	May 18 '26	Sale	20.04	15,000	300,579	362,152	May 20 04:07 PM
Cohlhepp Ryan	President and COO	May 15 '26	Option Exercise	3.79	8,000	30,318	204,141	May 18 04:24 PM
Cohlhepp Ryan	President and COO	May 15 '26	Sale	20.29	12,500	253,649	191,641	May 18 04:24 PM
Mazumdar Claire	Officer	May 18 '26	Proposed Sale	20.92	15,000	313,800		May 18 04:18 PM
Cohlhepp Ryan	Officer	May 15 '26	Proposed Sale	20.31	12,500	253,875		May 15 04:14 PM
Raben David	Chief Medical Officer	Apr 27 '26	Option Exercise	3.79	5,500	20,844	60,786	Apr 28 07:49 PM
Raben David	Chief Medical Officer	Apr 27 '26	Sale	22.88	5,500	125,830	55,286	Apr 28 07:49 PM
Raben David	Officer	Apr 27 '26	Proposed Sale	22.88	5,500	125,830		Apr 27 04:09 PM
Hyep Ivan	Chief Financial Officer	Apr 21 '26	Option Exercise	3.79	9,200	34,866	154,555	Apr 22 04:53 PM
Hyep Ivan	Chief Financial Officer	Apr 21 '26	Sale	23.00	9,200	211,614	145,355	Apr 22 04:53 PM
Hyep Ivan	Officer	Apr 21 '26	Proposed Sale	23.18	9,200	213,210		Apr 21 04:09 PM
Mazumdar Claire	Chief Executive Officer	Apr 16 '26	Option Exercise	4.54	22,760	103,359	362,152	Apr 20 07:27 PM
Mazumdar Claire	Chief Executive Officer	Apr 20 '26	Option Exercise	3.79	15,000	56,847	377,152	Apr 20 07:27 PM
Mazumdar Claire	Chief Executive Officer	Apr 20 '26	Sale	23.61	15,000	354,146	362,152	Apr 20 07:27 PM
Mazumdar Claire	Officer	Apr 20 '26	Proposed Sale	23.74	15,000	356,100		Apr 20 04:02 PM
Cohlhepp Ryan	President and COO	Apr 15 '26	Option Exercise	3.79	8,000	30,318	208,641	Apr 17 04:55 PM
Cohlhepp Ryan	President and COO	Apr 15 '26	Sale	23.01	12,500	287,591	196,141	Apr 17 04:55 PM
Cohlhepp Ryan	Officer	Apr 15 '26	Proposed Sale	22.98	12,500	287,250		Apr 15 04:06 PM
Raben David	Chief Medical Officer	Mar 25 '26	Option Exercise	3.79	5,500	20,844	60,786	Mar 26 07:21 PM
Raben David	Chief Medical Officer	Mar 25 '26	Sale	18.95	5,500	104,229	55,286	Mar 26 07:21 PM
Raben David	Officer	Mar 25 '26	Proposed Sale	18.95	5,500	104,229		Mar 25 04:01 PM
Hyep Ivan	Chief Financial Officer	Mar 23 '26	Option Exercise	3.79	9,200	34,866	154,555	Mar 24 07:45 PM
Hyep Ivan	Chief Financial Officer	Mar 23 '26	Sale	18.52	9,200	170,348	145,355	Mar 24 07:45 PM
Hyep Ivan	Officer	Mar 23 '26	Proposed Sale	18.60	9,200	171,120		Mar 23 04:04 PM
Mazumdar Claire	Chief Executive Officer	Mar 19 '26	Option Exercise	3.79	6,905	26,169	346,297	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 18 '26	Option Exercise	3.79	6,499	24,630	345,891	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 20 '26	Option Exercise	3.79	1,596	6,049	340,988	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 19 '26	Sale	18.78	6,905	129,705	339,392	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 18 '26	Sale	18.84	6,499	122,415	339,392	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 20 '26	Sale	18.95	1,596	30,246	339,392	Mar 20 05:02 PM
Mazumdar Claire	Officer	Mar 20 '26	Proposed Sale	18.95	1,596	30,246		Mar 20 04:08 PM
Mazumdar Claire	Officer	Mar 19 '26	Proposed Sale	18.78	6,905	129,705		Mar 19 04:27 PM
Mazumdar Claire	Officer	Mar 18 '26	Proposed Sale	19.19	6,499	124,716		Mar 18 04:26 PM
Cohlhepp Ryan	President and COO	Mar 16 '26	Option Exercise	3.79	8,000	30,318	213,141	Mar 17 05:36 PM
Cohlhepp Ryan	President and COO	Mar 16 '26	Sale	19.66	12,500	245,714	200,641	Mar 17 05:36 PM
Cohlhepp Ryan	Officer	Mar 16 '26	Proposed Sale	19.34	12,500	241,750		Mar 16 04:03 PM
Mazumdar Claire	Chief Executive Officer	Mar 09 '26	Option Exercise	3.79	36,766	139,336	376,158	Mar 11 04:47 PM
Mazumdar Claire	Chief Executive Officer	Mar 09 '26	Sale	19.17	36,766	704,657	339,392	Mar 11 04:47 PM
Mazumdar Claire	Officer	Mar 09 '26	Proposed Sale	19.17	36,766	704,657		Mar 09 04:06 PM
Mazumdar Claire	Chief Executive Officer	Mar 06 '26	Option Exercise	3.79	3,817	14,466	343,209	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 04 '26	Option Exercise	3.79	2,631	9,971	342,023	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 05 '26	Option Exercise	3.79	1,786	6,769	341,178	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 06 '26	Sale	18.75	3,817	71,572	339,392	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 04 '26	Sale	18.73	2,631	49,289	339,392	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 05 '26	Sale	18.74	1,786	33,464	339,392	Mar 06 07:27 PM
Mazumdar Claire	Officer	Mar 06 '26	Proposed Sale	19.80	3,817	75,572		Mar 06 04:01 PM
Cohlhepp Ryan	President and COO	Mar 03 '26	Option Exercise	3.79	12,892	48,858	222,533	Mar 05 07:10 PM
Cohlhepp Ryan	President and COO	Mar 03 '26	Sale	18.16	17,392	315,893	205,141	Mar 05 07:10 PM
Hyep Ivan	Chief Financial Officer	Mar 03 '26	Option Exercise	3.79	13,555	51,371	158,910	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 04 '26	Option Exercise	3.79	2,963	11,229	148,318	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 03 '26	Sale	18.22	13,555	246,910	145,355	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 04 '26	Sale	18.25	2,963	54,062	145,355	Mar 05 07:08 PM
Raben David	Chief Medical Officer	Mar 04 '26	Option Exercise	3.79	16,300	61,774	71,586	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 03 '26	Option Exercise	3.79	200	758	55,486	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 04 '26	Sale	18.52	16,300	301,920	55,286	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 03 '26	Sale	18.45	200	3,690	55,286	Mar 05 07:06 PM
Mazumdar Claire	Officer	Mar 05 '26	Proposed Sale	18.74	1,786	33,464		Mar 05 04:04 PM
Hyep Ivan	Officer	Mar 04 '26	Proposed Sale	18.25	2,963	54,062		Mar 04 04:32 PM
Mazumdar Claire	Officer	Mar 04 '26	Proposed Sale	18.73	2,631	49,289		Mar 04 04:31 PM
Raben David	Officer	Mar 04 '26	Proposed Sale	18.52	16,300	301,920		Mar 04 04:21 PM
Hyep Ivan	Officer	Mar 03 '26	Proposed Sale	18.22	13,555	246,910		Mar 03 04:48 PM
Raben David	Officer	Mar 03 '26	Proposed Sale	18.45	200	3,690		Mar 03 04:11 PM
Cohlhepp Ryan	Officer	Mar 03 '26	Proposed Sale	18.16	17,392	315,893		Mar 03 04:09 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 26 '26	Buy	16.00	300,000	4,800,000	4,603,418	Mar 02 04:22 PM
Cohlhepp Ryan	President and COO	Feb 25 '26	Option Exercise	3.79	3,108	11,779	213,272	Feb 27 04:13 PM
Cohlhepp Ryan	President and COO	Feb 25 '26	Sale	18.04	3,631	65,501	209,641	Feb 27 04:13 PM
Cohlhepp Ryan	Officer	Feb 25 '26	Proposed Sale	18.04	3,631	65,501		Feb 25 04:03 PM

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Ph.D.Dr. Claire Mazumdar Clemon M.B.A.

PresidentMr. Ryan Cohlhepp Pharm.D.

CFOMs. Jennifer Larson

Vice President of Investor Relations and Corporate CommunicationsMs. Rachel Frank

Chief Legal OfficerMs. Lara S. Meisner J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAX

Bicara Therapeutics Inc

Upgrade your Finviz experience